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GABA type-A (GABA-A) receptors containing the α2 subunit (GABRA2) are expressed
in most brain regions and are critical in modulating inhibitory synaptic function. Genetic
variation at the GABRA2 locus has been implicated in epilepsy, affective and psychiatric
disorders, alcoholism and drug abuse. Gabra2 expression varies as a function of
genotype and is modulated by sequence variants in several brain structures and
populations, including F2 crosses originating from C57BL/6J (B6J) and the BXD
recombinant inbred family derived from B6J and DBA/2J. Here we demonstrate a global
reduction of GABRA2 brain protein and mRNA in the B6J strain relative to other inbred
strains, and identify and validate the causal mutation in B6J. The mutation is a single
base pair deletion located in an intron adjacent to a splice acceptor site that only occurs
in the B6J reference genome. The deletion became fixed in B6J between 1976 and
1991 and is now pervasive in many engineered lines, BXD strains generated after 1991,
the Collaborative Cross, and the majority of consomic lines. Repair of the deletion using
CRISPR-Cas9-mediated gene editing on a B6J genetic background completely restored
brain levels of GABRA2 protein and mRNA. Comparison of transcript expression in
hippocampus, cortex, and striatum between B6J and repaired genotypes revealed
alterations in GABA-A receptor subunit expression, especially in striatum. These results
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suggest that naturally occurring variation in GABRA2 levels between B6J and other
substrains or inbred strains may also explain strain differences in anxiety-like or alcohol
and drug response traits related to striatal function. Characterization of the B6J private
mutation in the Gabra2 gene is of critical importance to molecular genetic studies
in neurobiological research because this strain is widely used to generate genetically
engineered mice and murine genetic populations, and is the most widely utilized strain
for evaluation of anxiety-like, depression-like, pain, epilepsy, and drug response traits
that may be partly modulated by GABRA2 function.
Keywords: GABRA2, C57BL/6J, GABA-A receptor, neuroscience, genetics, CRISPR (clustered regularly
interspaced short palindromic repeats)/Cas9, BXD mice strains, inbred mouse strains
INTRODUCTION
GABA-A receptors are pentameric ligand gated chloride channels
responsible for fast inhibitory neurotransmission. The sequence,
structure, and chromosomal location of receptors and their
cognate subunits are highly conserved among mammals (Olsen
and Sieghart, 2009). Receptors are typically composed of two α,
two β, and a γ or δ subunit, with the most common receptor
subtypes containing α1 or α2 subunits. Subunit composition can
alter receptor pharmacology and localization (Sieghart, 1995).
Receptors containing the α2 subunit (GABRA2) are abundantly
expressed in mouse hippocampus, frontal cortex, amygdala,
dorsal and ventral striatum, and hypothalamus—brain regions
important for motivation, reward, anxiety, depression, and fear.
Over 500 common human variants have been identified at
the GABRA2 locus, including numerous intronic variants, a
handful localized to the UTRs, and one synonymous variant
in exon 4. Genetic variation at this locus has been linked to
alcohol dependence (Covault et al., 2004; Edenberg et al., 2004;
Lappalainen et al., 2005; Agrawal et al., 2006; Enoch et al.,
2006; Fehr et al., 2006; Lind et al., 2008a,b; Soyka et al., 2008;
Villafuerte et al., 2013; Li et al., 2014), the subjective effects
of alcohol (Pierucci-Lagha et al., 2005; Roh et al., 2011; Uhart
et al., 2013; Arias et al., 2014), excess EEG fast activity (Lydall
et al., 2011), cocaine reward (Dixon et al., 2010), substance
dependence (Enoch et al., 2010), epilepsy (International League
Against Epilepsy Consortium on Complex Epilepsies, 2014), and
impulsivity and insula cortex activity during reward or loss
anticipation (Villafuerte et al., 2013). Furthermore, interactions
between early life stress and GABRA2 polymorphisms may
influence vulnerability to addiction (Enoch, 2008; Dick et al.,
2009; Enoch et al., 2010). However, the impact of these variants
on expression, isoform usage, or function of GABRA2 protein
or mRNA is unclear (Myers et al., 2007; Heinzen et al.,
2008; Gibbs et al., 2010; Liu et al., 2010; Kim et al., 2014;
Lieberman et al., 2015).
Preclinical models can be useful in dissecting enigmatic
relationships between human behavior and genetic variation.
Genetically engineered mouse models in which Gabra2
expression or sensitivity to modulation has been altered
(knock-out and knock-in) suggest a role for GABA-A receptors
containing the α2 subunit in depression (Vollenweider et al.,
2011), alcohol intake and behavioral response to alcohol (Boehm
et al., 2004; Blednov et al., 2011, 2013; Liu et al., 2011), anxiety
(Dixon et al., 2008), and cocaine-conditioned reinforcement and
behavioral sensitization (Morris et al., 2008; Dixon et al., 2010).
Genetic deletion of Gabra2 is also associated with a decrease
in miniature inhibitory postsynaptic current in the nucleus
accumbens core (Dixon et al., 2010), suggesting an important
role of GABRA2 in modulating inhibitory signaling in this
region. However, no studies to date have characterized naturally
occurring variants segregating among murine populations that
could alter GABRA2 levels or function, and provide insight into
the role of human variants.
In this study, we leverage naturally occurring variation in
murine populations of varying genetic complexity in order
to better understand the role of Gabra2 variants on gene
function. We previously profiled gene expression data from
multiple strains and crosses, including nearly isogenic C57BL/6
substrains and the well-characterized BXD family of strains
derived from a cross between B6J and DBA/2J (D2) inbred mice,
to characterize genetic variation in Gabra2 expression (Mulligan
et al., 2012). Here we identify a spontaneous intronic deletion
in B6J that underlies variation in GABRA2 protein and mRNA
expression across diverse murine populations that incorporate
B6J as a progenitor strain. We have quantified molecular
consequences of the private mutation in B6J by CRISPR-Cas9
genome editing. This work demonstrates the functionality of
often ignored non-coding variants in the mouse genome and
characterizes the downstream consequences of Gabra2 variation
on molecular traits.
MATERIALS AND METHODS
Mice
B6(Cg)-Tyrc−2J/J mice were purchased from Jackson Laboratory
and C57BL/6NCrl mice were purchased from Charles River
Laboratories at 8-weeks-of-age and allowed to acclimate
for 9 days at UTHSC before tissue collection. C57BL/6J,
DBA/2J, C57BL/6NJ, C57BL/6JEiJ, and C57BL/6ByJ were
maintained in-house up to generation 6 at UTHSC from Jackson
Laboratory stock. BXD mice were maintained at UTHSC.
The B6-Gabra2em1Geh/J CRISPR repair line (homozygous
Gabra2KI/KI) was generated at the University of Pittsburgh
(as described below) and is maintained as a heterozygous
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breeding colony by the Mulligan laboratory at UTHSC. All
mice were housed in same-sex cages, allowed ad-lib access to
food and water and maintained on a 12h/12h light/dark cycle
in a climate-controlled facility. Only adult mice between 70
and 200 days of age were included in the study. All animal
care and handling procedures were approved by the UTHSC
and the University of Pittsburgh Institutional Animal Care
and Use Committees.
Data Sets Used
The following data sets available at GeneNetwork.org were
used in the analysis: GN76 OHSU/VA B6D2F2 Brain mRNA
M430 (Aug05) RMA (Hitzemann et al., 2004), GN84 OHSU/VA
B6D2F2 Striatum M430v2 (Sep05) RMA (Hitzemann et al.,
2004), GN281 INIA Hypothalamus Affy MoGene 1.0 ST
(Nov10) (Mozhui et al., 2012), GN323 INIA Amygdala Cohort
Affy MoGene 1.0 ST (Mar11) RMA, GN110 Hippocampus
Consortium M430v2 (Jun06) RMA (Overall et al., 2009), GN175
UCLA BHHBF2 Brain (2005) mlratio (Orozco et al., 2009; van
Nas et al., 2010), GN171 UCLA CTB6/B6CTF2 Brain (2005),
mlratio, INIA LCM (11 Regions) BASELINE RNA-seq Transcript
Level, GN206 UMUTAffy Hippocampus Exon (Feb09) RMA, and
GN732 GTEXv5 Human Brain Hippocampus RefSeq (Sep15)
RPKM log2 (Lonsdale et al., 2013). In addition to references
provided, additional information on these data sets can also be
found at GeneNetwork.org.
Tissue Collection
The cortex, hippocampus, and striatum (dorsal and ventral)
were dissected from up to three males and three females for
each strain (effective strain n = 5 or 6). At time of tissue
harvest, purchased mice were ∼9 weeks and in-house strains
were ∼8 weeks of age. Tissue was immediately frozen in liquid
nitrogen and stored at −80◦C until further use. Additional
peripheral tissue, including the liver and spleen, was also
dissected from each strain and stored at −80◦C until further
use. Whole brains from wild-type Gabra2B6J/B6J, homozygous
Gabra2KI/KI and heterozygous Gabra2KI/− mice were dissected
and placed in glass scintillation vials, which were subsequently
kept at −80◦C. To prepare for sub-dissection of whole frozen
brains, the brains were kept at −20◦C at least 30 min prior
to dissection. Whole brains were placed dorsal side down into
a brain matrix, with two coronal cuts being made by single
edge razor blades to obtain striatal tissue. The first cut was
made rostral and proximal to the optic chiasm (bregma −3.0),
and the second cut was made two millimeters forward from
the first cut (bregma +2.0). Hippocampus and cortex were
then sub-dissected from the brain tissue remaining caudal
to the first razor blade cut. Gabra2 homozygous knockout
brains were kindly provided by Y. Blednov at the University
of Texas at Austin. These mice were maintained on a mixed
C57BL/6Jx129/SvEv background at the University of Sussex
and were backcrossed twice to B6J at the University of Texas.
Tissue was flash frozen in liquid nitrogen, and immediately
(within 1–2 days) shipped on dry ice to UTHSC where cortex,
hippocampus, and striatum were dissected and stored at –80◦C
until further use.
qPCR to Validate mRNA Levels
Five biological replicates were used for each strain and consisted
of both males and females (two or three of each sex). RNA
was isolated from brain tissue using the RNeasy Lipid Tissue
kit (Qiagen), with cDNA then being generated from 1 µg
of RNA utilizing the First Strand Reverse Transcriptase kit
(Roche). Quantitative PCR was performed to assess target
gene expression using the KAPA SYBR Fast QPCR Master
Mix, probes from Roche’s Universal ProbeLibrary, custom
primers from Integrated DNA Technologies (IDT), and a Roche
Light Cycler 480 II. Universal probes and custom primers
were selected and designed, respectively, using the Universal
Probe Library (LifeScience). For Gabra2 (NM_008066.3) we
used Universal Probe #103 and the following primers: Left–
ACAAAAAGAGGATGGGCTTG and Right–TCATGACGGAG
CCTTTCTCT. Cyclophilin D (NM_026352.3) was selected as
the endogenous control for all tissues (Schmittgen and Livak,
2008). Data was analyzed using the 11Ct method as described
in Livak and Schmittgen (2001), with B6J selected as the reference
or calibrator strain to calculate fold-change expression. For gene
expression in the CRISPR mice, the coefficient of variation
was quantified using the 1Ct method. All statistical tests were
conducted in R using R Studio (RStudio: Integrated Development
for R. RStudio, Inc., Boston, MA, United States). One-way
ANOVA was performed when comparing more than two
independent samples and Tukey’s HSD post hoc test subsequently
applied to assess pairwise significance between genotypes.
Validation of Genomic Variants
Variants that were polymorphic between the B6J reference
genome and B6NJ and D2 were identified using 100X
coverage of the D2 genome1 (Wang et al., 2016) and
the Welcome Trust Sanger Institute (sequenced genomes
available for 36 inbred mouse strains, including the B6NJ
substrain2). Initially we identified two high quality indels located
on Chr 5 at 71,014,638 bp (deletion) and 71,031,384 bp
(rs225241970, deletion), and a highly conserved intergenic
SNP located at 70,931,531 bp (all coordinates given based on
the GRCm38/mm10 assembly). Genomic DNA was extracted
from B6J, D2, B6NJ, B6EiJ, B6ByJ, BXD29, and BXD40
using the DNeasy Blood & Tissue Kit (Qiagen) from frozen
liver or spleen tissue. Variants were genotyped using primers
designed against the reference genome using the Primer3Plus
web tool and purchased from IDT. Primers targeting each
variant include: (1) SNP rs29547790@70,931,531 bp Left–
AAAAGTCAGGGTGTGGTTGG and Right–GGAGTGCAGC
TCTCTCTTTTGG, (2) indel@71,014,638 bp Left–TCAGGA
GTCCAGATTTTGCTG and Right–TCTCTCAGTTCCGTTTT
CTGTAA, and (3) indel rs225241970@71,031,384 bp Left–AG
CACCCTTGGGAAGAAAGG and Right–GGTCTCATCAGGA
AATAGAACCGA. Genomic intervals (∼100–300 bp) containing
the variants were amplified by PCR and unincorporated
nucleotides and primers removed using ExoSAP-IT (Thermo
Fisher Scientific). Traditional Sanger capillary sequencing
1http://ucscbrowser.genenetwork.org/
2http://www.sanger.ac.uk/cgi-bin/modelorgs/mousegenomes/snps.pl
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was performed by the UTHSC Molecular Resource Center
Institutional Core using the ABI Prism 3130 Genetic Analyzer
system. The only variant that could not be confirmed was the
indel rs225241970 located on Chr5 at 71,031,384 bp as none
of the seven strains tested, including B6J, were polymorphic
at this position. This genomic region includes a microsatellite
repeat (CA)n that may have led to sequencing errors in the
reference genome.
Traditional Western Analysis
Lysates were prepared from frozen tissue and protein
concentration was determined using a NanoDrop 2000
Spectrophotometer (Thermo Fisher Scientific). 50 µg of
total protein was loaded and separated on a 7.5% SDS-PAGE
gel. Proteins were transferred using the Bio-Rad Turbo Transfer
system and blocked for 30 min at room temperature. For
chemiluminescence western blots, blots were incubated in
primary antibody for GABRA2 (1:500 rabbit polyclonal,
PhosphoSolutions, Cat #822-GA2CL) overnight at 4◦C. Blots
were washed three times (5 min each) with blocking buffer and
incubated with horseradish-peroxidase conjugated antibody
for 1 h at room temperature. Blots were developed using
the Super Signal West Pico Chemiluminescent Substrate kit
(Thermo Fisher Scientific #34080) on a BioRad ChemiDoc
imaging system. Blots were then incubated in a stripping
solution (Restore Western Blot Stripping Buffer, Thermo Fisher
Scientific #21059) for 8 min, re-probed overnight at 4◦C with
a GAPDH antibody (1:5000, mouse monoclonal, Fitzgerald,
Cat #10R-G109A), and developed again the following day. For
fluorescent western blots, blots were incubated with both primary
antibodies together overnight at 4◦C, followed by anti-rabbit
and anti-mouse fluorescent-conjugated antibodies. Visualization
was performed using an Odyssey image scanner. Blot intensities
across all blots were quantified using ImageJ. Original blots can
be found in Supplementary Figures S1, S2.
Proteomics Analysis by 6-Plex
TMT-LC/LC-MS/MS
The analysis was performed essentially based on the previously
reported protocol (Bai et al., 2017; Niu et al., 2017). In brief,
hippocampus was dissected from male B6J and D2 mice to
create pooled samples consisting of three animals each. Pooled
samples represented B6J mice aged approximately 60 days (two
pooled samples) or 1 year (one pooled sample) and D2 mice aged
90 days (two pooled samples) or 1 year (one pooled sample).
Tissue from pooled samples was lysed and digested into peptides.
After desalting, the peptides were labeled with TMT reagents and
equally mixed. The labeled samples were further fractionated by
neutral pH reverse phase liquid chromatography (LC). A total
of 10 fractions were collected and further analyzed by low pH
reverse phase LC, and each fraction was analyzed by acidic pH
reverse phase LC-MS/MS.
Collected data was searched against a database to identify
peptides and filtered to achieve a 1% protein false discovery
rate. TMT intensities were extracted, filtered, normalized, and
summarized into peptide and protein quantification results.
A total of 22,005 proteins representing 7,074 protein groups were
identified and 7,014 protein groups were quantified. Statistical
analysis was performed to determine cutoff for altered proteins
and to evaluate associated false discovery rate. In this case the
significance threshold was set at p < 0.005 with a minimum
of 3 peptides detected. A total of 8 peptides and 34 spectral
counts were detected for GABRA2 (full data set provided in
Supplementary Table S1).
Generation of CRISPR-Engineered Mice
Knockin mice (B6-Gabra2em1Geh/J or Gabra2KI/KI)
were produced with CRISPR/Cas9 using techniques
as described (Blednov et al., 2017). Briefly, a sgRNA
targeting Gabra2 at the intron/exon junction near Chr 5 at
71,014,638 bp (GRCm38/mm10 assembly) was identified
using the WTSI Genome Editing database (Hodgkins
et al., 2015). Two partially overlapping PCR primers
(F:GAAATTAATACGACTCACTATAGGAATTGTAAATTTATA
TTTGTTTTAGAGCTAGAAATAGC; R:AAAAGCACCGACG
TGCCACTTTTTCAAGTTGATAACGGACTAGCCTTATTTTA
ACTTGCTATTTCTAGCTCTAAAAC) were used to generate
a T7 promoter containing sgRNA template (sgRNA target
sequence underlined in above sequence) as described (Bassett
et al., 2014). The sgRNA and Cas9 mRNA were produced
by in vitro transcription, purified using the MEGAclear Kit
(Ambion), ethanol precipitated, and re-suspended in DEPC
treated water. A 121 nucleotide single stranded DNA repair
template oligo (TTTATAGGCTTACTACTTCTAAAACATGTA
CTGTTTTCAAAGGAATTGTAAATTTATATTTTAGGAGTAT
ACAATAGATGTTTTCTTTCGGCAAAAATGGAAAGATGAG
CGTTTAAAATTT) harboring the desired T insertion (bold,
italic in above sequence) in the intron of Gabra2 was purchased
as Ultramer DNA (Integrated DNA Technologies, Coralville,
IA). sgRNA (100 ng/µl), Cas9 mRNA (75 ng/µl), and repair
oligo (100 ng/µl) were injected into the cytoplasm of B6J one-cell
embryos as described (Yang et al., 2014; Blednov et al., 2017).
Pups resulting from injected embryos were screened for DNA
sequence changes in intron 3 of the Gabra2 gene by PCR/DNA
sequence analysis. Briefly, a 447 bp amplicon spanning the
knockin site was PCR amplified with forward (CAACCAGGAGG
GGAAAGACA) and reverse (TTCGAAGCAGCTTGTTTGGC)
primers. PCR products were sequenced directly or subcloned
into pCR2.1-TOPO (Invitrogen) and sequenced. All mice were
genotyped by DNA sequence analysis (Sanger sequencing)
using this approach.
The male founder (F0) was subsequently crossed to a
female B6J mouse to generate F1 progeny. F1 mice were
crossed to generate F2 mice. The colony is maintained through
heterozygous breeding and all molecular phenotyping was
performed in generations F2 and higher.
Analysis of CRISPR/Cas9 Off-Target
Effects
The CRISPOR program v4.03 was used to search for off-
target sites (Haeussler et al., 2016). For precise genome editing,
3crispor.tefor.net
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the sgRNA must match a 20 nucleotide target sequence in
the genomic DNA (protospacer sequence) that includes a
protospacer adjacent motif (PAM) with sequence NGG (where
N is any nucleotide). The sgRNA target sequence (TGAATCAT
AAACTTATATTTAGG) and PAM used to generate CRISPR-
engineered mice was predicted to generate 245 off-targets using
CRISPOR. However, all predicted off-targets included two (8
predicted off-target sites), three (57 predicted off-target sites),
or four (380 predicted off-target sites) mismatches in the
12 bp adjacent to the PAM site. Perfect matches are more
likely to generate off-target effects compared to mismatches.
All off-targets were given an off-target score [cutting frequency
determination or CFD score (Doench et al., 2016)] in CRISPOR.
We ranked candidates by the CFD score and selected the top
15 predicted off-target sites for confirmation using traditional
capillary sequencing (described above). All of these sites
contained at least 4 mismatches and were located in intergenic or
intronic regions (Supplementary Table S2) with high sequence
complexity and repetitive sequences. As a result, two of the
primer pairs failed to produce a PCR product, even when using
B6J genomic DNA.
Analysis of Global Gene Expression in
CRISPR-Engineered Gabra2 Mice
Cortex, hippocampus, and striatum were harvested from three
male and three female Gabra2B6/B6 and Gabra2KI/KI mice aged
100 to 130 days-of-age as described above. RNA was extracted
using the RNeasy Lipid Tissue kit (Qiagen) and contaminating
genomic DNA was removed following treatment with RNase-free
DNAse (Qiagen). RNA quantity was measured using a NanoDrop
2000 spectrophotometer (Thermo Fisher Scientific) and quality
was assessed using the RNA nano chip and Bioanalyzer
(Agilent). All samples had RNA integrity values (RIN) over
8. Gene expression was measured using the mouse Clariom
D Assay (Thermo Fisher Scientific). Sample preparation and
hybridization were performed according to the manufacturers
protocol and performed by the UTHSC MRC Institutional
Core. Affymetrix Expression Console Software (Thermo Fisher
Scientific) was used to annotate and process raw probe cell
intensity files. The Gene Level-SST-RMA algorithm was used to
perform signal space transformation (SST) and guanine cytosine
count correction prior to robust multi-array average (RMA)
normalization on the batch of 36 samples (3 brain regions × 2
sexes × 3 biological replicates × 2 genotypes). There were
no outliers following normalization. The data set was filtered
to include only “Main” category probe sets corresponding to
annotated coding and non-coding transcripts with a variance
>0.1 across all samples. This reduced the data set from 72,688 to
12,699 probe sets. This data set was used for enrichment analysis
and to investigate possible changes in other α subunits following
reduction of Gabra2. For each analysis, genes with differential
expression between Gabra2KI/KI and Gabra2B6/B6 were detected
using Students t-test in R to compare expression of each gene
by genotype. A nominal p-value was used for both analyses (no
adjustment for multiple testing) because of the exploratory nature
of enrichment analysis and in order to perform the comparative
analysis across GABAA receptor subunit genes. Male and female
samples of each genotype were pooled for the analysis.
Enrichment analysis was performed for differentially
expressed genes (p < 0.01, n = 684) in the striatum
using WebGestalt (Zhang et al., 2005; Wang et al., 2013).
Overrepresentation of functional terms in the differentially
expressed gene set compared to the reference set (consisting
of the 12,699 filtered probe sets) was calculated using the
Overrepresentation Enrichment Analysis (ORA) method using
the following functional databases: Gene Ontology (GO)
biological process, GO cellular component, GO molecular
function, KEGG, and mammalian phenotype ontology
(MPO). Significant enriched terms were identified using
the following criteria: (1) minimum number of three genes
in a category and (2) a False Discovery Rate (FDR) of <0.05
or nominally significant p-value < 0.01. For analysis of
compensatory changes, the expression of all 19 major subunits
was compared between genotypes in the cortex, striatum,
and hippocampus.
RESULTS
Reduced Levels of Gabra2 Occur Only in
the B6J Substrain
The B6J strain showed the lowest levels of Gabra2 among
16 common and wild-derivative inbred strains, including the
closely related C57BL/6ByJ substrain (Figure 1A). This difference
was robustly detected across expression platforms and brain
regions. For example, average log2 expression of Gabra2 in the
hippocampus was 9.3 for B6J and 11.2 for D2 with over 3.6-
fold variation across inbred strains of mice (Affymetrix M430
array, Figure 1A). The decrease in Gabra2 mRNA levels was
global, and this reduction relative to D2 was also detected in
10 mesocorticolimbic regions (RNA-seq, Figure 1B). To evaluate
whether reduced levels of Gabra2 were only evident in B6J, we
examined expression in a small pedigree of C57BL/6 substrains
with defined dates of separation—B6J, B6(Cg)-Tyrc−2J/J (B6C2J),
C57BL/6EiJ (B6EiJ), C57BL/6JByJ (B6ByJ), C57BL/6NJ (B6NJ),
and C57BL/6NCrl (B6NCrl) (Figure 1C). Of these substrains,
B6EiJ was the most recently separated from B6J in 1976. The
albino strain (B6C2J) was maintained as an inbred colony since
the discovery of the albino mutation around 1970 (Townsend
et al., 1981) but over the past decade has been repeatedly
backcrossed to B6J stock and is therefore now listed as a congenic
(Cg) strain of B6J rather than as an independent substrain.
Expression of Gabra2 in cortex, striatum, and hippocampus was
significantly higher (p < 0.05) in B6EiJ, B6ByJ, B6NJ, B6NCrl,
and D2 as compared to B6J and B6C2J (Figure 1D). These
results explain the remarkable variation in Gabra2 levels (over
4-fold) observed both within sets of BXD strains based on
time of generation between the late 1970’s and the early 2000’s
(Taylor et al., 1999; Peirce et al., 2004) (Figures 1D–E and
Supplementary Figure S3) and recent crosses between B6J and
C3H/HeJ or B6J and CAST/EiJ (Mulligan et al., 2012). Lower
expression in these crosses was always associated with inheritance
of the B6J parental allele of Gabra2. F2 intercrosses can also be
Frontiers in Genetics | www.frontiersin.org 5 March 2019 | Volume 10 | Article 188
fgene-10-00188 March 27, 2019 Time: 17:51 # 6
Mulligan et al. Functional Gabra2 Mutation in B6J
FIGURE 1 | Continued
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FIGURE 1 | Strain variation in Gabra2 expression. (A) Low expression of Gabra2 in B6J brain relative to other inbred strains and substrains. B6J demonstrated the
lowest expression of Gabra2 in hippocampus (data set GN110, probe set 1421738_at) compared to 15 inbred strains, including the D2 strain, and a closely related
B6 substrain (C57BL/6ByJ). (B) Gabra2 levels measured by RNAseq are reduced in 10 mesocorticolimbic regions relative to D2, indicating a global reduction in B6J.
BLA = basolateral amygdala, BST = bed nucleus stria terminalis, DLS = dorsolateral striatum, DMS = dorsomedial striatum, ILC = infralimbic cortex, NAc = nucleus
accumbens core, NAs = nucleus accumbens shell, PrL = prelimbic cortex, VCX = visual cortex, VTA = ventral tegmented area. All Ps < 0.001 for within region
contrasts between B6J and D2. (C) Approximate time line seperating C57BL/6 substrains. (D) Average Gabra2 expression level (measured by qPCR) in the cortex,
hippocampus, and striatum of D2, C57BL/6 substrains, and congenic strains relative to B6J shown at left. The B6N lineage (seperated in 1951 at generation F32
from B6J) includes C57BL/6JByJ (B6ByJ), C57BL/6NCrl (B6NCrl), and C57BL/6NJ (B6NJ) and all showed higher expression of Gabra2 relative to B6J. Even the
C57BL/6EiJ (B6EiJ) substrain that diverged most recently from C57BL/6J in 1976 showed higher brain expression of Gabra2. The only substrain with low Gabra2
expression similar to C57BL/6J is the B6(Cg)-Tyrc−2J/J (B6C2J) congenic strain. This albino mutation was detected in 1970 but the original strain harboring the
spontaneous mutation was backcrossed to B6J creating a congenic line. All statistical contrasts performed relative to B6J. (E) Derivation of BXD strain cohorts.
Each cohort was derived by separate crossing and inbreeding of female B6J (black) and male D2 (gray) parental inbred strains. The first cohort of BXD strains (1
through 32) was derived in the late 1970s. Another set of strains (33 through 42) was produced in the early 1990s. The last cohort of BXD strains (43 to 100) was
created in the early 2000 s. (F) Hippocampal differences in Gabra2 expression between earlier and later derived BXD strains. There was little difference in the
expression of Gabra2 between BXD strains with the B6 or D2 allele in the first cohort. However, inheritance of the B6 allele in the later two cohorts was associated
with a dramatic reduction in Gabra2 expression. This suggests the appearance of a mutant allele in the B6J line that occurred after the late 1970’s and prior to 1990.
Data from GeneNetwork data set GN110, probe set 1421738_at. (G) Protein levels of GABRA2 were reduced in B6J relative to D2 using an unbiased shotgun
proteomics approach. Relative expression of GABRA2 protein shown as normalized relative intensity for GABRA2 in B6J and D2 hippocampus. Eight different
peptide sequences that matched GABRA2 were used to generate normalized relative intensity counts for each sample. Each sample is 3 pooled animals (males
only). (H) Hippocampal protein levels of GABRA2 are reduced in B6J (n = 3) compared to the closely related B6N (n = 3) substrain and D2 (n = 2) strain (Western blot
analysis). The experiment was repeated twice and both B6J sample 1 and B6N sample 1 were run each time. Tissue from Gabra2 KO mice and their wild type
control strain (WT) were kindly provided by Y. Blednov at The University of Texas. These mice were originally maintained on a mixed B6J and 129/SvEv background
but were backcrossed twice to B6J upon arrival at The University of Texas, thus the WT control strain has low GABRA2 protein expression similar to B6J. ANOVA for
effect of strain is significant [F (2,5) = 103.9, p < 0.001]. Post hoc tests show B6J is different from both B6N and D2 (p < 0.001) but B6N and D2 are not significantly
different from each other (p = 0.15). Significance defined as: #p < 0.1, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.
used to estimate the effect of each allele on expression and mode
of inheritance. In F2 crosses in which B6J is a parental strain, the
B6J allele was completely recessive (Supplementary Figure S4).
Taken together, there is strong evidence that a spontaneous
mutation in the Gabra2 gene was fixed in the B6J foundation
stock colony at the Jackson Laboratory between 1976 and 1991.
This mutation greatly reduces brain expression of Gabra2 mRNA
in B6J and all known derivative strains.
To evaluate whether the private B6J mutation also leads to
a reduction in protein level, we measured GABRA2 expression
using traditional Western blots and shotgun proteomics
methods. We first compared expression between B6J and D2
using a hippocampal proteome dataset generated using the
tandem mass tag (TMT) approach. Significantly (p < 0.005)
less GABRA2 normalized peptide counts were detected in B6J
(0.77 ± 0.04) relative to D2 (1.23 ± 0.07) (Figure 1G). To
confirm and expand upon this finding, we probed with antibodies
specific for GABRA2 in the hippocampus and also detected a
marked reduction in protein levels in the B6J strain compared
to both the D2 strain and the B6NJ substrain (Figure 1H and
Supplementary Figure S1).
Identification of Candidate Non-coding
Sequence Variants Modulating Gabra2
Expression
The Gabra2 gene resides in a genomic region that is largely
identical by descent among inbred strains, with the exception
of the wild derived strains (e.g., CAST/EiJ, PWK/PhJ, and
SPRET/EiJ) and contains very few known sequence variants,
most of which are located within intronic or intergenic regions.
B6J and derivative congenic strains, such as B6C2J, are the
lowest expressing individuals from a panel of inbred strains
and C57BL/6 substrains (Figure 1). Thus, the causal sequence
variant must share a common pattern that differentiates B6J
from all other inbred strains and substrains. To identify
candidate variants near the Gabra2 locus we used existing
resources generated by our group [100X coverage of the D2
genome4 (Wang et al., 2016)] and the Wellcome Trust Sanger
Institute (>30X average coverage of the genomes of 36 inbred
mouse strains, including the B6NJ substrain5). Using these
resources, we identified one SNP and two insertion/deletions
(indels) that were of high sequence quality. All three were
private to B6J compared to B6NJ and D2. We were able to
independently validate one SNP and one indel by capillary-
based dideoxynucleotide sequencing. Validated candidate
polymorphisms were located either ∼30 Kb downstream of the
Gabra2 gene locus in an intergenic region with high conservation
among the mammalian lineage (SNP rs29547790 located on Chr
5 at 70,931,531 bp) or in an intron (the third nucleotide from
exon 4) adjacent to a splice acceptor site (indel located on Chr 5
at 71,014,638 bp) (Figure 2A).
To identify the causal variant, we genotyped D2, C57BL/6
substrains, and BXD strains that differed in the level of Gabra2
expression based on inheritance of the presumed wild type allele
prior to the late 1970s (D2, B6ByJ, B6NJ, B6EiJ and BXD29) or the
mutant allele which was fixed in the B6J substrain between 1976
and 1991 (B6J and BXD40). Importantly, only the genotype at the
intronic variant was perfectly associated with Gabra2 expression
levels (Figure 2A). Strains with the mutant allele (single base
deletion), such as B6J and BXD40, had low expression of Gabra2
compared to the five strains with the wild type allele. The intronic
variant was located near a splice acceptor site but the specific
4http://ucscbrowser.genenetwork.org/
5http://www.sanger.ac.uk/cgi-bin/modelorgs/mousegenomes/snps.pl
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FIGURE 2 | Identification of a B6J private variant in Gabra2. (A) Position of variants near the Gabra2 gene locus. An intergenic SNP (yellow arrowhead) and a single
nucleotide indel (red arrowhead) in the third intron were the only confirmed variants among B6J and other inbred mouse strains. Genotyping of strains with high (red)
or low (blue) expression of Gabra2 revealed that the likely causal variant is the intronic indel (single base pair deletion in B6J). (B) Evidence for disruption of mRNA
processing is shown as an accumulation of intronic reads in the affected intron three (designated with an asterisk) and downstream introns (four and five) in B6J (blue)
compared to D2 (red). Normalized and binned read pileup of poly-A enriched striatal RNA-seq data from 10 to 11 B6 and D2 individuals, respectively, generated by
Bottomly and colleagues (Bottomly et al., 2011) and hosted for viewing and analysis at the GeneNetwork mirror of the UTHSC Genome Browser (http://ucscbrowser.
genenetwork.org/). Gabra2 gene model is shown above (5′ to 3′ orientation with dashed line representing introns and solid vertical bars representing exons).
(Continued)
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FIGURE 2 | Continued
(C) Average hippocampal expression of Gabra2 exons and introns based on inheritance of B6J (B) and D2 (D) alleles in the BXD population. All coding exons and
UTRs showed significantly higher expression associated with inheritance of the D allele. In contrast, introns 4, 5, and 6 showed significantly higher expression
associated with inheritance of the B allele. The variant is located in intron 3. Introns 3, 6 (distal to the fifth coding exon), 7, and 8 are not significantly different based
on expression of parental alleles. There was no evidence of a splicing defect resulting in loss of exons in B6J. GeneNetwork data set GN206, UMUTAffy
Hippocampus Exon (Feb09) RMA was used for the analysis and includes 45 BXD strains from BXD33 and above. 15 strains inherited the B allele and 30 inherited
the D allele at the Gabra2 locus. Significance was determined by a pair-wise comparison of B and D allele expression for each intron or exon using Student’s t-test.
Significance defined as: #p < 0.1, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.
impact on splicing is not known. However, striatal RNA-seq
data (Bottomly et al., 2011) generated for B6J (n = 10) and D2
(n = 11) revealed a higher number of reads mapping both to the
intron containing the enigmatic deletion and two downstream
introns in the B6J strain (Figure 2B) which could indicate errors
in mRNA processing. Significantly higher intronic expression
(probe 4462485; p< 0.001) was also detected among BXD strains
(BXD33 through 100) that inherited the B6J allele (6.1 ± 0.22)
compared to those that inherited the D2 allele (5.06± 0.13) using
an exon microarray platform (GeneNetwork data set GN206,
UMUTAffy Hippocampus Exon (Feb09) RMA; Figure 2C). All
Gabra2 exons are expressed at the mRNA level in BXD strains
regardless of allele, suggesting that the variant does not produce
alternative mRNA isoforms. Instead, all coding exons have higher
expression in strains that inherited the D2 (D) allele, and three
introns containing or immediately downstream of the variant
have higher expression in strains that inherited the B6J (B) allele
(Figure 2C). In sum, a non-coding intronic deletion is the sole
candidate variant responsible for decreased GABRA2 protein and
mRNA expression in B6J.
Repair of the Candidate Non-coding
Variant Is Sufficient to Restore GABRA2
Levels in the B6J Genetic Background
To test whether the intronic deletion is sufficient to globally
reduce brain mRNA and protein in B6J we used the CRISPR
(clustered regularly interspaced short palindromic repeats)
and CRISPR associated (Cas9) system to repair the mutation
on a pure B6J genetic background (B6-Gabra2em1Geh/J;
Figure 3A). Insertion (knockin; KI) of a single nucleotide was
sufficient to fully restore GABRA2 protein (Figure 3B and
Supplementary Figure S2) and mRNA levels (Figure 3C) in
brain tissue of B6-Gabra2em1Geh/J homozygous knockin (KI,
Gabra2KI/KI) and heterozygous (HET, Gabra2KI/B6J) F2 offspring
(Figure 3D). These results are consistent with the recessive
mode of inheritance of the mutant and hypomorphic B6J allele
(Gabra2B6J/B6J) that is associated with reduced expression due
to the presence of the intronic deletion. The use of CRISPR
engineering can produce both off-target effects and founders
that are mosaic for the introduced mutation (e.g., some cells
may have the mutation, some may not, and other cells may have
different mutations). However, the expression level of GABRA2
protein and mRNA in the brain tissue of the founder mouse
was equivalent to strains without the Gabra2 deletion (e.g., ByJ
and NJ; Figures 3B,C) indicating correction in most, if not
all, neurons of the founder mouse. In addition, no off-target
modifications were detected in the top 15 predicted off-target
sites in the F0 mouse and his progeny compared to the B6J
reference genome (see section “Materials and Methods” and
Supplementary Table S2).
Intronic Gabra2 Deletion Is Associated
With Alterations in GABAergic Striatal
Gene Expression and Signaling
To precisely identify biological processes or pathways altered
by variation in Gabra2 levels in the striatum, hippocampus,
and cortex, we performed enrichment analysis on genes
differentially expressed (p < 0.01; 684 genes) between
homozygous Gabra2KI/KI mice with “normal” Gabra2
levels and “mutant” Gabra2B6J/B6J mice with low levels of
Gabra2. No significantly enriched categories were observed for
differentially expressed genes from the cortex or hippocampus.
However, a number of enriched categories (FDR adjusted
p-value <0.05) related to GABAergic synaptic signaling
were detected in striatum, including ion transmembrane
transport, localization to the synapse, GABA receptor activity,
retrograde endocannabinoid receptor signaling, dopaminergic
synapse, cAMP signaling pathway, and GABAergic synapse
(Supplementary Tables S3, S4). Mammalian Phenotype
Ontology terms related to emotional behavior, cognition, anxiety,
sensorimotor gating, fear, and reward were also enriched, albeit
only at a nominally significant level. These results indicated
that alterations in GABAergic signaling, specifically in the
striatum, might be a direct downstream consequence of reduced
Gabra2 levels.
Alterations in GABAergic signaling could result from the loss
of GABRA2-containing receptors or changes in the composition
of GABA-A receptors to reflect inclusion of other alpha subunits
in the absence of GABRA2. To begin to address these issues,
we compared the transcript levels of all major GABA-A receptor
subunits (α1-6; β1-3, γ1-3, and δ) in multiple brain regions
between homozygous Gabra2KI/KI mice with normal Gabra2
levels and mice harboring the mutant B6J allele (Gabra2B6J/B6J).
In addition to a large and significant reduction in Gabra2
mRNA, the transcript levels of several major GABA-A receptor
alpha subunits (Gabra1, Gabra3, Gabra5) were also significantly
reduced in striatum of Gabra2B6J/B6J mice relative to the
Gabra2KI/KI mice (Figure 4). In contrast, the level of Gabra4 was
modestly increased in Gabra2B6J/B6J mice. In striatum, alterations
in alpha subunits were accompanied by significant decreases in
beta (1 and 2) and gamma (1 and 2) subunits and a significant
increase in the delta subunit (B6J allele relative to KI allele;
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FIGURE 3 | Repair of the private deletion in B6J is sufficient to restore GABRA2 protein and mRNA levels. (A) Site of repair of the private deletion in B6J (green),
guide RNA (red) and PAM site (blue) are shown. The exon is highlighted in yellow. (B) Protein levels of GABRA2 are also restored in the hippocampus (top panel) and
cortex (bottom panel) of the original Gabra2KI/KI founder mouse (n = 1) relative to B6J (n = 3) and are similar to that of B6NJ (n = 3). Western blot shown to the left
and adjusted density bar graph shown to the right for each region. (C) Hippocampal and cortical Gabra2 mRNA levels were restored in the original Gabra2KI/KI
founder after insertion of a single nucleotide relative to B6J. Expression of Gabra2 in the founder mouse was similar to that of other B6 substrains. Expression was
measured via qPCR and shown relative to B6J. Males and females were combined for the statistical analysis (n = 5 to 6 per strain). Note that CRISPR founders can
often be mosaic for the introduced mutation such that some cells may have the mutation, some may not, and other cells may have different mutations. We include
molecular validation in the founder in order to demonstrate that our engineering approach worked, and that mosaicism is not evident in brain tissue of the
Gabra2KI/KI founder mouse. Tissue from Gabra2 knockout mice (KO, predominately B6J background mixed with 129/SvEv, see section Materials and Methods) was
kindly provided by Y. Blednov from The University of Texas and used as a negative control. (D) Hippocampal, striatal, and cortical Gabra2 mRNA levels were also
restored in heterozygous Gabra2KI/− and homozygous knockin Gabra2KI/KI mice after insertion of a single nucleotide relative to homozygous Gabra2B6J/B6J mice.
Expression measured via qPCR and data were analyzed at the 1Ct level (relative to the expression of the control gene Cyclin D). There is a significant main effect of
genotype [F (2,32) = 47.1, p = 2.9e-10] and brain region [F (2,32) = 27.89, p = 9.7e-08]. The interaction was not significant. Pairwise significance between genotypes
and within brain region were determined using Tukey’s HSD test. Significance defined as: #p < 0.1, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.
Figure 4). Highly significant alterations in alpha subunits were
not observed in the hippocampus or cortex between genotypes,
but there was a trend for increased expression of both the α1
subunit in the cortex and the α3 subunit in the hippocampus (B6J
allele relative to KI allele). In the cortex there was an associated
trend for increased expression of the β2 subunit and decreased
expression of the γ1 subunit. In the hippocampus, there was a
significant decrease in γ1 subunit levels and a trend for decreased
expression of the β1 and γ3 subunits. Taken together, these results
indicate that decreased levels of GABRA2 associated with the B6J
allele are likely to be associated with profound alterations in the
level and composition of GABA-A receptor subunits, especially
in the striatum.
DISCUSSION
Using a combination of genetic, genomic, functional, and
bioinformatics approaches we have identified a private and
non-coding single nucleotide deletion in the Gabra2 gene
in the B6J strain that results in substantial reduction of
brain mRNA and protein levels (Figures 1, 2). Repair of
this deletion using CRISPR-Cas9 genome editing fully restores
GABRA2 levels (Figure 3) on the B6J genetic background.
The resulting genetically engineered rodent model system
(Gabra2B6J/B6J and Gabra2KI/KI mice) is thus, a valuable
resource for probing the molecular and behavioral consequences
of alterations in GABRA2 expression. These results have
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FIGURE 4 | Expression of GABA-A receptor subunit mRNA. Expression generated using the Affymetrix Clariom D Assay (microarray platform). Only subunits with
significant or suggestive (p < 0.1) differential expression between B6J and KI Gabra2 genotypes are shown. Significance defined as: ∗p < 0.05, ∗∗p < 0.01,
∗∗∗p < 0.001. Fold change is indicated by color intensity with yellow representing increased expression in Gabra2B6J/B6J (B6J allele) mice relative to Gabra2KI/KI (KI
allele) mice. In contrast, blue represents decreased expression in B6J allele mice relative to KI allele mice. Alterations in the mRNA levels of several alpha subunits,
including the major Gabra1 subunit, are observed in the cortex and striatum of B6J allele mice which harbor a naturally occuring intronic deletion resulting in
decreased Gabra2 expression. The only alpha subunit with significant and higher levels of mRNA expression (fold change >1.3) in B6J allele mice is Gabra4
(striatum). Beta and gamma subunit mRNAs are also altered at a suggestive level in cortex and hippocampus. In the hippocampus, γ1 transcript expression is
significantly reduced in mice with the B6J allele. In the striatum, β1-2 and γ1-γ2 transcripts are also significantly reduced in mice with the B6J allele of Gabra2. In
contrast, striatal levels of delta subunit mRNA is increased in mice with the B6J allele relative to those with the KI allele. These results suggest brain region specific
alterations in the abundance of certain classes of GABA-A receptors associated with inheritance of the Gabra2 B6J allele. For example, in the cortex,
α1β2-containing receptors may be increased while α2γ1-containing subunits may be decreased. In the hippocampus, α2 and α3-containing receptors including β1
or γ1-γ2 subunits may be decreased. In the striatum there is evidence that there may be a general decrease in receptors containing α1, α2, α3 or α5; and β1 or 2;
and γ1 or γ2. In contrast, there may be an increase in receptors containing α4 and δ subunits in striatum.
important implications for any investigators using B6J as
their background strain for molecular genetic studies of
neurobiology and behavior, in particular those involving study of
the GABAergic system.
Unlike previous studies in which function of Gabra2
was probed through complete genetic deletion, the mutation
associated with the B6J allele of Gabra2 is hypomorphic and
not a complete null. Complete deletion of function represents
an extreme case in biological systems and there are often
many adaptive changes that can make interpretation of results
difficult. Substitution by other α subunits has not been profiled
extensively in Gabra2 KO mouse lines and some differences
in behavior could be due to enhanced expression of other
subunits and differences in genetic background because existing
Gabra2 KO mice differ in the proportion of B6J and 129/SvEv
genetic background. In contrast, our study probed the role
of natural variation in the level of Gabra2 in the context of
an isogenic B6J background and profiled the expression of all
major GABA-A subunits in cortex, striatum, and hippocampus—
regions involved in different aspects of memory, mood disorders
and addiction. Surprisingly, even in the context of an isogenic
B6J background, we detected many alterations in GABAergic
signaling at the transcriptional level and observed changes in
GABA-A receptor subunit expression between Gabra2B6J/B6J
and Gabra2KI/KI in all three regions with the most profound
alterations detected in the striatum. Regardless of brain region,
the major alteration (fold change >2.5) was the reduction
in Gabra2 expression. However, the levels of other alpha
subunits were also altered (Figure 4), albeit at much lower
levels (<1.5 fold). Exceptions include the levels of Gabra5
(1.7 fold decrease relative to Gabra2KI/KI) and Gabra3 (2.5
fold decrease relative to Gabra2KI/KI) in the striatum. There
are no known mutations in Gabra3 or Gabra5 in the B6J
background, so the reduction in their levels in striatum is
almost certainly a direct result of the reduction in Gabra2.
Based on the available data, our hypothesis is that there are
simply fewer α2 containing GABA-A receptors in B6J derived
strains, and possibly fewer GABA-A receptors in some regions.
This is supported by the trend toward decreased cortical
α2:γ1 transcript levels, decreased hippocampal α2:β1:γ1 and
α2:β1:γ3 transcript levels, and decreases in multiple alpha, beta,
and gamma transcript levels in the striatum of Gabra2B6J/B6J
relative to Gabra2KI/KI. The pronounced impact of the B6J
mutation on GABA-A receptor subunit mRNA expression in
the striatum, combined with the involvement of the striatum
in anxiety and behavioral sensitization to alcohol and other
drugs of abuse, strongly suggests that alterations in the level
of Gabra2 in this region drive related behavioral differences
between mice with the low-expressing B6J allele and the
high-expressing wild type allele. Future functional studies
exploring behavior and inhibitory neurotransmission across
multiple brain regions in B6-Gabra2em1Geh/J genotypes will test
this hypothesis.
Overall, the findings of our study have broad implications
for both mouse and human research. Despite numerous
associations between human GABRA2 variants and addiction-
related traits, the mechanisms underlying these associations
are unclear. To date, there is no direct link between variants
in GABRA2 and alterations in gene expression or function
in human brain. However, if functional variants in GABRA2
exist, they are almost certainly non-coding variants that exert
a functional impact through alteration of splicing or gene
regulation, or mRNA stability as opposed to variants resulting in
a complete loss of function. This may be similar to the function
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of the non-coding variant controlling variation in Gabra2
levels in crosses involving B6J and in our B6-Gabra2em1Geh/J
preclinical model system and suggests that non-coding variants
in GABRA2 in human populations might be functional and
causal. Evaluating and confirming the functional impact of
these variants in human populations is extremely difficult
due to the complexity of human genetics and environmental
factors, as well as the limited ability to assay brain gene
expression and circuitry. Therefore, preclinical models such as
ours are of vital importance for generating new hypotheses,
endophenotypes, and underlying molecular mechanisms to test
in human populations. This might include the generation of
humanized mice in which candidate functional GABRA2 variants
are introduced into the Gabra2 corrected B6J genetic background
that is permissive for detection of variants that modulate
Gabra2 expression.
We discovered a functional variant causing reduced Gabra2
expression in B6J, the mouse reference genome and the
most widely used inbred strain in biomedical research. It is
now critical to re-evaluate gene deletion and other studies
in light of the naturally occurring mutation in Gabra2. For
example, the Gabra2 locus was recently posited to be a
modifier of genetic deletion of Scn1a, a voltage-gated sodium
channel gene implicated in a spectrum of seizure-related
disorders in humans (Hawkins et al., 2016). Hawkins and
colleagues observed that the genetic background of Scn1a+/−
mutations impacted the severity of the epilepsy phenotype
such that mutations generated on a B6J background had
increased seizures and premature death compared to the
same mutation on a 129S6/SvEvTac background, which
had a normal phenotype. Our study suggests a specific
hypothesis, namely that reduced GABRA2 expression and
alterations in GABAergic signaling comprise the causal
mechanism underlying enhanced seizure susceptibility induced
by Scn1a deletion on the permissive B6J background. Likewise,
because the B6J strain is also the most widely used strain
for biomedical research, several findings in this strain
may be confounded by alterations in GABRA2 and other
GABA-A subunits. However, as long as investigators are
aware of gene variants with a large impact on expression
and function, such as the non-coding variant in Gabra2,
these naturally occurring mutations can be vital tools for
discovery and systems genetics (Li et al., 2010; Mulligan
and Williams, 2015; Wang et al., 2016). The CRISPR-Cas9
B6J Gabra2 repaired line (B6-Gabra2em1Geh/J) will serve
as a crucial resource for directly testing the role of Gabra2
variation related to phenotypic differences in B6J derived
lines and substrains.
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FIGURE S1 | Original blots from Figure 1H analysis. Blots were incubated
overnight with anti-GABRA2 antibody (PhosphoSolutions #822-GA2CL), followed
by a horseradish peroxidase-conjugated anti-rabbit secondary, and developed on
a BioRad ChemiChem chemiluminescent detection system. (A) Unedited
whole-blot GABRA2 staining. Following development, blots were stripped and
re-probed for GAPDH (Fitzgerald #10R-G109A) as a loading control, and
developed using the same protocol. (B) Unedited whole-blot GAPDH staining.
(C,D) show equivalent whole-blot unedited images from a second replicate of the
experiment. Samples B6J-1 and B6N-1 were run during both experiments.
FIGURE S2 | Original blots from founder mouse analysis in Figure 3B. Blots were
incubated overnight with anti-GABRA2 (PhosphoSolutions #822-GA2CL) and
anti-GAPDH (Fitzgerald #10R-G109A) antibodies, followed by
fluorescent-conjugated secondary antibodies, and developed on an Odyssey
imaging system. (A,B) show unedited whole-blot GABRA2 and GAPDH staining of
cortex samples, respectively. (C,D) show corresponding GABRA2 and GAPDH
uncropped whole-blot images that have been edited using Photoshop’s
brightness/contrast and levels features to make bands visible. (E–H) show
equivalent images for blots containing hippocampal samples.
FIGURE S3 | Strain distribution pattern of expression of Gabra2. A 2 to 3-fold
reduction in expression of mRNA levels in hippocampus [GN110 Hippocampus
Consortium M430v2 (Jun06) RMA] that is only segregating in the new BXD strains
(BXD33 and higher) that have inherited the Gabra2 B6J private mutation. The
Y-axis provides an estimate of the expression of Gabra2 (Affymetrix probe set
1455444_at) on log2 scale. To the far left are the two reciprocal F1 hybrids
between B6J and D2 with comparatively normal high expression, demonstrating a
dominant phenotype of the wild type D allele. Note that all of the initial set of BXDs
(from BXD1 to BXD32) have high expression, a finding only compatible with the
hypothesis that the mutation in B6J occurred after the inception of these strains.
In contrast, 15 of the newer BXD strains have low expression. Finally, all other
common inbred strains, including both B6ByJ and all parental strains of the
Collaborative Cross other than B6J have high expression. High expression is also
evident in the CXB recombinant inbred panel generated by crossing BALB/cByJ
and B6ByJ. Bars colored by genotype or inbred strain. BXD genotype determined
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using marker rs13478320 located on Chr 5 at 70,742,059 bp. CXB genotype
determined using marker rs13478300 located on Chr 5 at 65,043,224 bp.
FIGURE S4 | Mode of inheritance of Gabra2 alleles. In a large eQTL transcriptome
analysis of 400 F2 intercross progeny between B6J and CAST/EiJ, the LOD peak
is precisely aligned on the Gabra2 gene (purple triangle), the effect size is about
0.20 z per allele (right Y-axis). Note also that the dominance effect is complete
(compare peak of the purple and green effect size plots).
TABLE S1 | Relative protein expression of the hippocampus in C57BL/6J and
DBA/2J mice profiled by 6-plex TMT-LC/LC-MS/MS. A total of 18 hippocampal
samples from 3- and 12-month-old C57BL/6J and DBA/2J mice were used in this
study. Three hippocampal samples were lysed and pooled into 6 groups (3 groups
per strain). The samples were analyzed by 6-plex TMT-LC/LC-MS/MS. TMT report
ion intensities were extracted and summarized for each protein. Gene Symbol:
extracted from the UniProt database; protein accession: from the UniProt
databases; PSM#: the total number of peptide-spectrum matches for each
protein; peptide#: the total number of peptides identified for each protein; Relative
protein abundance: the ratio of the ion intensity of each sample and the average of
6 samples; p-value: p value calculated by t statistics. A total of 7,014 unique
proteins were quantified.
TABLE S2 | Summary of Predicted Off-Targets. Predictions made using the
CRISPOR program and prioritized based on CFD score.
TABLE S3 | Overrepresented functional terms for differentially expressed genes in
the striatum of CRISPR engineered Gabra2 KI mice. Gene members are shown for
categories with less than 20 members. All gene members for each category are
shown in Supplementary Table S4.
TABLE S4 | Summary of genes with significantly enriched functional terms.
Summary of results are provided in the first worksheet (C = total number of genes
in category; O = number of observed genes in category; E = number of genes in
category expected by chance). Remaining worksheets contain all enriched
categories and genes.
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